Fundraising FoxCARMAT
1 known investors
Find your way into CARMAT
Sign up to see every warm intro you have to CARMAT
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CARMAT team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.
Investors · 1
Frequently asked questions
- What does CARMAT do?
- CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.
- Who are CARMAT's investors?
- CARMAT's investors include Air Liquide Venture Capital (ALIAD).